S-1: Alpha Cognition Files for Resale of 1.4 Million Common Shares Following ZUNVEYL Approval

Alpha Cognition has filed a registration statement for the resale of 1.4 million common shares by existing stockholders, following the recent FDA approval of their Alzheimer's drug, ZUNVEYL.

Summary

• Alpha Cognition has filed a registration statement for the resale of up to 1,447,666 common shares by existing stockholders.
• These shares include 801,413 common shares issued upon conversion of convertible notes and 646,253 common shares issuable upon exercise of warrants.
• The company will not receive any proceeds from the sale of these shares.
• The selling stockholders may offer these shares from time to time through public or private transactions.
• Alpha Cognition recently received FDA approval for ZUNVEYL, a treatment for mild to moderate Alzheimer's disease.
• The company is also developing other pre -clinical programs, including a combination of ZUNVEYL with memantine for moderate to severe Alzheimers, a sublingual formulation of ZUNVEYL, and an intranasal formulation for mild traumatic brain injury.
• The company completed a 1 -for-25 reverse stock split on November 5, 2024.
• The company's common shares are now trading on the Nasdaq Capital Market under the symbol ACOG.

Sentiment

Score: 7

Explanation: The document is generally positive due to the FDA approval of ZUNVEYL and the company's listing on the Nasdaq. However, there are also significant risks and challenges highlighted, including the need for additional capital and the competitive landscape.

Positives

• The company has received FDA approval for ZUNVEYL, a treatment for mild to moderate Alzheimers disease.
• The company has a pipeline of pre -clinical programs, including a combination of ZUNVEYL with memantine for moderate to severe Alzheimers.
• The company has successfully listed on the Nasdaq Capital Market.
• The company has a strong management team with experience in drug development and commercialization.

Negatives

• The company will not receive any proceeds from the sale of the shares being registered.
• The company has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company has a limited operating history and no history of commercializing products.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives.

Risks

• The company's ability to generate revenue and achieve profitability depends significantly on the successful commercialization of ZUNVEYL and the development of other product candidates.
• The company may encounter substantial delays in its preclinical studies and clinical trials.
• The use of the company's therapeutic candidates could be associated with side effects, adverse events or other safety risks.
• The company faces significant competition in an environment of rapid technological and scientific change.
• The company relies on third -party suppliers to manufacture its product candidates.
• The company is subject to certain supply chain risks inherent in manufacturing its lead product, ZUNVEYL, with respect to Taiwan.
• The company's product candidates have never been manufactured on a commercial scale.
• The successful commercialization of the company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels.
• The company currently has no sales organization.
• The company's stock price may be volatile.
• An active, liquid and orderly market for the company's common shares may not develop.
• The company is an emerging growth company and a smaller reporting company and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, the company's common stock may be less attractive to investors.
• The company may be a passive foreign investment company under United States tax laws.

Future Outlook

The company expects ZUNVEYL to be available by prescription in pharmacies nationwide by the second quarter of 2025 and plans to complete the out -license of its TBI asset into Alpha Seven in Q1 2025.

Management Comments

• The company will now focus on the development of commercial manufacturing and commercial sales of ZUNVEYL oral tablet formulation.
• The company plans to continue its commercialization preparations around ZUNVEYL.
• The company plans to complete the out -license the TBI asset into Alpha Seven in Q1 2025, where Alpha Seven plans to raise the additional capital to advance the TBI program.

Industry Context

The document highlights the limited treatment options for neurodegenerative diseases, particularly Alzheimer's, and the dissatisfaction with existing treatments, which positions ZUNVEYL as a potential solution with a differentiated profile. The company is targeting the long -term care market, which is a significant segment for Alzheimer's treatments.

Comparison to Industry Standards

• The document mentions that current acetylcholinesterase inhibitor medications are absorbed in the gastrointestinal system and bind to locally present acetylcholinesterase, leading to gastrointestinal side effects.
• ZUNVEYL is designed as a prodrug to eliminate drug absorption in the gastrointestinal tract, potentially addressing certain tolerability issues.
• The document notes that current symptomatic treatments for Alzheimers disease provide limited symptom improvement and cause difficult to manage tolerability side effects.
• The document states that many providers and caregivers believe the approved generic medications provide limited efficacy and adverse effects.
• The document mentions that Biogen will discontinue marketing Aduhelm by the end of 2024, highlighting the challenges in developing effective treatments for Alzheimers disease.
• The document notes that Adlarity, a transdermal formulation of donepezil, was the most recently FDA approved symptomatic treatment in 8 years, in March 2022, highlighting the limited innovation in this space.
• The document states that since 2003, over 500 clinical studies in Alzheimers have been completed and only Aduhelm, Adlarity and now ZUNVEYL have been approved by the FDA, compared to higher success rates for all other drug candidates.

Management Changes

Related Party Transactions

• The company has a promissory note with Neurodyn Life Sciences Inc., a related party through a common director.
• The company has a loan agreement with Alpha Seven Therapeutics Inc., a related party through a common director and officers.
• Two holders of 5% or more of the company's outstanding securities participated in the bridge financing transaction.

Stakeholder Impact

• Shareholders may experience dilution from the resale of shares and potential future capital raises.
• Employees may benefit from the company's growth and potential commercial success.
• Customers (patients) may benefit from the availability of new treatment options for Alzheimer's disease.
• Suppliers and creditors may benefit from the company's increased activity and potential for growth.

Next Steps

• Begin commercialization of the FDA -approved ZUNVEYL oral formulation.
• Continue commercialization preparations around ZUNVEYL.
• Complete the out -license the TBI asset into Alpha Seven in Q1 2025.

Key Dates

Keywords

ZUNVEYL, Alzheimer's disease, biopharmaceutical, FDA approval, common shares, resale, convertible notes, warrants, Nasdaq, reverse stock split, neurodegenerative diseases, mild traumatic brain injury, acetylcholinesterase inhibitor, memantine, orphan drug designation